Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a

Vandetanib trifluoroacetate (D6474 trifluoroacetate) is an orally active and potent VEGFR2/KDR tyrosine kinase inhibitor with an IC50 value of 40 nM. Vandetanib trifluoroacetate also showed inhibition of VEGFR3/FLT4 and EGFR/HER1, with IC50 values of 110 nM and 500 nM respectively.

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 (IC50: 40 nM). It also inhibits VEGFR3 and EGFR.

Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity with IC 50 of 40 nM. Vandetanib hydrochloride also has some additional activity versus the tyrosine kinase activity of VEGFR3/FLT4 ( IC 50 =110 nM) and EGFR/HER1 ( IC 50 =500 nM) [1].